CN105476012B - A kind of special medicine purposes formula food and preparation method thereof - Google Patents
A kind of special medicine purposes formula food and preparation method thereof Download PDFInfo
- Publication number
- CN105476012B CN105476012B CN201510998050.8A CN201510998050A CN105476012B CN 105476012 B CN105476012 B CN 105476012B CN 201510998050 A CN201510998050 A CN 201510998050A CN 105476012 B CN105476012 B CN 105476012B
- Authority
- CN
- China
- Prior art keywords
- lactalbumin
- peptide
- special medicine
- compound
- thousandth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 100
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 100
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 68
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 29
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 29
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000304 folic acid Drugs 0.000 claims abstract description 12
- 235000019152 folic acid Nutrition 0.000 claims abstract description 12
- 239000011724 folic acid Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 10
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 10
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000004365 Protease Substances 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 26
- 229940088598 enzyme Drugs 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 23
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 239000005862 Whey Substances 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 13
- 235000019419 proteases Nutrition 0.000 claims description 13
- 108090000526 Papain Proteins 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000000378 dietary effect Effects 0.000 claims description 9
- 235000019834 papain Nutrition 0.000 claims description 9
- 229940055729 papain Drugs 0.000 claims description 9
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000002249 anxiolytic agent Substances 0.000 claims description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 108010004032 Bromelains Proteins 0.000 claims description 3
- 230000000049 anti-anxiety effect Effects 0.000 claims description 3
- 235000019835 bromelain Nutrition 0.000 claims description 3
- 108091005508 Acid proteases Proteins 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 235000021119 whey protein Nutrition 0.000 abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 229920001184 polypeptide Polymers 0.000 abstract description 9
- 206010070834 Sensitisation Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000008313 sensitization Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 description 25
- 238000006460 hydrolysis reaction Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 210000000078 claw Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- -1 there are trypsase Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000047670 Viola x wittrockiana Species 0.000 description 1
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a kind of special medicine purposes formula foods and preparation method thereof, and its prepare the purposes of Medicines.It is the niacin of whey protein peptide one thousandth to 5/1000ths that the lactalbumin small peptide being prepared, which includes the folic acid and quality of hundred a ten thousandths to a ten thousandth that quality is whey protein peptide, molecular weight less than 1000 dalton whey protein peptide up to 98% or more.Product according to the present invention has high activity, high-absorbility, high nutrition, high security, feature without side-effects.Method of the present invention may make lactalbumin sufficiently to digest, whey protein peptide yield is high, whey protein peptide obtained is predominantly made of the mixtures of polypeptides that 2~5 amino acid form, it is highly susceptible to body absorption, sensitization further decreases, Product Activity is higher, and preparation method is easy to operate, the application suitable for industrialized production.
Description
Technical field
The invention belongs to biochemical field, it is related to a kind of special medicine purposes formula food and preparation method thereof, and
Its purposes for preparing Medicines, more particularly to a kind of by digesting lactalbumin, the whey protein peptide being prepared,
With and preparation method thereof and a kind of purposes for preparing Medicines.
Background technique
The research of newborn source biologically active peptide starts from 1979, and German Brantl et al. is obtained by digesting bovine casein
Some polypeptide products, and prove that they have class morphine activity, research in terms of this people expands biologically active peptide.Through
Nearly exploration in 20 years is crossed, up to the present, it has been found that a variety of cream sources biologically active peptide.ACE of the foreign countries to milk protein sources
Peptide for inhibiting research is more deep, and especially Japan carries out the ace inhibitory peptide in lactalbumin, casein and Yoghourt
More research, makes great progress.It is domestic at the early-stage to research in this respect at present.Lactalbumin is industrial life
The protein in liquid by-product whey during production cheese or casein.It has high absorptivity, fat and contents of saccharide
It is extremely low, while the features such as sulfur-containing amino acid rich in, having improves angiocarpy, diabetes, infant nutrition, anti-aging, mentions
The healthcare functions such as high immunity.Lactalbumin is formed with its good protein, high biological utilisation value and special life
Manage function, by international extensive concern, sport nutrition, health care and in terms of application prospect it is wide
It is wealthy.
Whey protein fraction analysis, the preparation of whey polysaccharide polypeptide, enzymatic hydrolysis are concentrated mainly on to lactalbumin research at present
In the research of technique and antioxidant activity.Contain the biologically active peptide of a large amount of different activities, these peptides or nature in lactalbumin
Be present in lactalbumin or the product after lactoprotein hydrolysis, since its molecular weight is smaller, small enteral can complete peptide
The form of section is absorbed by the body.Lactalbumin can not only significantly improve its dissolubility, stability, emulsification through protease hydrolytic
Property, frothing capacity etc., and the peptide fragment generated after degrading is easier to the absorption, transhipment and utilization of body.In addition, by whey
The enzymatic hydrolysis of albumen can effectively destroy some sensitization structures, to eliminate its sensitization, will not cause the immunological rejection of human body,
And there are a variety of special physiological active functions.
Lactalbumin obtains small molecule whey protein peptide through protease hydrolyzed, and whey protein peptide is mainly by 2-7 amino
The mixtures of polypeptides of acid composition, is a kind of multifunctional and nutritional factor, has immunological regulation, antithrombotic, anti-hypertension, drop gallbladder solid
A variety of physiological active functions such as alcohol, antibacterial can be made into natural hypotensor, patient's nutritional supplement, infant food, old food
Product, sports food and various functional health foods etc., can be widely applied to the industries such as food and medicine.
Currently, the preparation of newborn source biologically active peptide mainly uses enzymatic isolation method, the proteolytic enzyme used based on single enzyme,
Mainly there are trypsase, pepsin, alkali protease, neutral proteinase, papain etc., and for most of lactoproteins
For the preparation of the biologically active peptide in source, the bioactivity peptide content of single enzyme method preparation is low, and separation and purification difficulty are big.State
It is inside and outside there are also produced about composite protease hydrolysis lactalbumin whey protein peptide research report, but also be mainly more than
The two kinds or more of enzyme-linked conjunctions of trypsase, pepsin, alkali protease, neutral proteinase, papain are stated, it is expected that
It improves hydrolysis result and improves the content of polypeptide.However, above-mentioned all methods still have, cumbersome, starting whey albumen is dense
Spend low, active peptide low yield, it is at high cost the defects of.There are also certain difficulty for the industrialized production of newborn source biologically active peptide.
The content of invention
To solve the above problems, the present invention provides a kind of special medicine purposes dietetic foods, wherein being cream comprising quality
The folic acid and quality of hundred a ten thousandths of albumin peptide to a ten thousandth are the cigarette of whey protein peptide one thousandth to 5/1000ths
Acid, molecular weight less than 1000 dalton whey protein peptide up to 98% or more.
To solve the above problems, the present invention also provides a kind of method for preparing above-mentioned special medicine purposes dietetic food,
Characterized by the following steps:
(1) the lactalbumin suspension that preparation mass percent is 1%-25%；
(2) hundred a ten thousandths that quality is lactalbumin are added into lactalbumin suspension to the folic acid of a ten thousandth or thousand
5/1 mono- to thousand niacin；
(3) compound protease is added into lactalbumin suspension to be digested；
(4) it will be concentrated after compound protein enzyme-deactivating；
(5) product after concentration is spray-dried to get compound lactalbumin peptide product.
Wherein, the concentration preferred mass percentage of the lactalbumin suspension is 5%-20%.
Wherein, the concentration of the folic acid 5/0.ths 5 to 100,000/preferably 100000ths.
Wherein, the content of compound protease described in step (3) is 0.1% one the 1% of lactalbumin amount.
Wherein, compound protease described in step (3) is by subtilopeptidase A (Bioprase SP-20), Yeast protein
Enzyme Denazyme AP, papain, flavor protease, bromelain, trypsase, neutral proteinase, animal protein water
Solve two or more any composition in enzyme, acid protease and pepsin.
Wherein, the composition of two kinds of compound proteases is according to (1-5): the weight ratio of (5-1) composition, preferably according to
(1-3): the weight ratio composition of (3-1), preferably according to (1-2): the weight ratio composition of (2-1).
Wherein, the time of the enzymatic hydrolysis of step (3) is 1-10 hours.
To solve the above problems, the present invention also provides a kind of special medicine purposes dietetic foods for treating phrenoblabia
Purposes, have medical application antianxity.
To solve the above problems, the present invention also provides a kind of dietetic food of above-mentioned special medicine purposes or according to above-mentioned
The product of method preparation is used to prepare the purposes of the drug for the treatment of phrenoblabia, particularly for preparing the drug of antianxiety purposes.
Product according to the present invention has high activity, high-absorbility, high nutrition, high security, feature without side-effects.
Method of the present invention may make lactalbumin sufficiently to digest, and whey protein peptide yield is high, and whey protein peptide obtained is main
Mixtures of polypeptides to be made of 2~5 amino acid forms, and is highly susceptible to body absorption, Product Activity is higher, lactalbumin
Abundant thorough enzymolysis destroys some sensitization structures, to further decrease its sensitization, reduces lactalbumin and causes human immunity
A possibility that rejection, and preparation method is easy to operate, the application suitable for industrialized production.
Specific embodiment
Below in conjunction with specific embodiment, the invention will be further elaborated.But examples are merely exemplary for these,
It is not intended to limit the scope of the present invention in any way.It will be understood by those skilled in the art that without departing from essence of the invention
Can be with the details and forms of the technical scheme of the invention are modified or replaced under mind and range, but these modifications and replacement are fallen
Enter in protection scope of the present invention.
(1) measuring method introduction:
1. peptide molecular weight distribution determination method
The molecular weight and content of analysis gained whey polypeptide are measured using high performance gel filtration chromatography.
Determining instrument and method:
(1) chromatographic condition: chromatographic column: TSKGEL2000SW × L (specification 7.8mm × 300mm × 5um)；Mobile phase: trifluoro
Acetic acid: acetonitrile: water=0.07:15:85；Detection wavelength: 214nm；Applied sample amount: 20 μ L；Flow velocity: 0.5mUmin.
(2) molecular weight standards the production of standard curve: are made into the standard items that mass concentration is 5mg/mL with mobile phase
Solution, using relative retention time as abscissa, the logarithm of molecular weight is ordinate, makees standard curve.
(3) measurement of whey polypeptide molecular weight distribution: whey polypeptide sample 0.5mg to be measured is taken, mobile phase is added to be diluted to
The solution of 5mg/mL makees test solution after miillpore filter (0.45um) filtering.Content is calculated with area normalization method；According to opposite
Retention time, reference standard curve calculate molecular weight.
2. hydrolyzed whey protein degree measuring method
(1) in solution soluble nitrogen measuring method (microdiffusion)
It takes lactalbumin to digest clarified solution 5ml, 1g digestion catalyst and the 10ml concentrated sulfuric acid is added, is digested at high temperature to Huang
After green, taking-up is cooled to room temperature, and adds water constant volume.Then it takes 5ml to be added to the mistress of diffusion boat, and adds in the interior room of diffusion boat
4ml concentrated NaOH solution is added into mistress, and covers cover plate rapidly for the boric acid solution for entering 2ml.It is placed in natural conditions left for 24 hours
Behind the right side, boric acid solution is titrated to pansy with the hydrochloric acid solution of standard.
Content (%)=(V2-Vl) × NH × 0.014 × extension rate/example weight × 100%
Note:
Vl: hydrochloric acid solution volume (ml) needed for blank；
V2: titration prepare liquid usage standard acid volume (ml)；
NH: standard acid normality；
The grams of 0.014Iml equivalent nitrogen.
(2) measuring method-trichloroacetic acid method of degree of hydrolysis
Addition 10ml trichloroacetic acid in 10ml zymolyte is taken, 20min is heated in a water bath, then in 4000r/min revolving speed
Lower centrifugation 15min.
Degree of hydrolysis is common is defined as: and degree of hydrolysis (DH)=(total peptide bond number in hydrolyzed peptide bond number/raw material) ×
100%, degree of hydrolysis (DH)=(nitrogen content-blank sample nitrogen content of the lactalbumin after digesting)/(cream can also be expressed as
Nitrogen content-blank sample nitrogen content of the albumin without enzymatic hydrolysis)
(2) test material
Lactalbumin is purchased from Henan Ji Mei Chemical Co., Ltd. and New Zealand's Dairy Raw Materials Co., Ltd.；Pepsin
1200000 u/g, 2,500,000 u/g of trypsase (Sinopharm Chemical Reagent Co., Ltd.)；850,000 u/g of bromelain, pawpaw egg
White 800,000 u/g of enzyme (Nanning Pang Bo Biotechnology Co., Ltd), (Shanghai Baofeng biochemistry is limited by 2,000,000 u/g of neutral proteinase
Company)；Subtilopeptidase A (Bioprase SP-20), endotrypsin Denazyme AP can from Negase Chemte ×
Purchase；Standard molecular weight reagent ribalgilase, actrapid monotard, human growth hormone (HGH) release inhibiting factor are Chinese drug biology system
Product examine fixed output quota product.
(3) embodiment
Embodiment 1
50g lactalbumin is weighed, aquation is configured to the lactalbumin suspension of 1.0wt%, is added into lactalbumin suspension
Quality be lactalbumin amount millionth folic acid and 5/1000ths niacin, into lactalbumin suspension be added quality be
0.1% trypsase and papain (being formed according to the weight ratio of 2:1) of lactalbumin amount.45 DEG C of constant temperatures
Under, fully transparent solution is obtained after enzyme hydrolysis 1h in constant temperature enzymatic vessel.Through detecting, the degree of hydrolysis of lactalbumin is 36.5%, so
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C afterwards and keeps 20min, inactivates enzyme.Degree of hydrolysis is controlled, so
Afterwards by the concentration of resulting lactalbumin peptide solution, spray drying, 190 DEG C of inlet air temperature, 95 DEG C of leaving air temp, feed rate are controlled
40ml/min obtains powdered compound lactalbumin peptide product.Through detecting, lactalbumin peptide content prepared by the present embodiment
(in terms of butt) is up to 98.5%；Peptide molecular weight distribution are as follows: account for 99% less than 1000 dalton.
Embodiment 2
50g lactalbumin is weighed, aquation is configured to 5.0wt% lactalbumin suspension, matter is added into lactalbumin suspension
Amount is 5/100000ths folic acid and 3/1000ths niacin of lactalbumin amount, and whey is added into lactalbumin suspension
The Bioprase SP-20 and papain (being formed according to the weight ratio of 3:1) of protein content 0.2%, 40 DEG C of constant temperatures
Under, fully transparent solution is obtained after enzyme hydrolysis 6h in constant temperature enzymatic vessel.Through detecting, the degree of hydrolysis of lactalbumin is 41.2%, so
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C afterwards and keeps 20min, inactivates enzyme, controls degree of hydrolysis, so
Afterwards by the concentration of resulting lactalbumin peptide solution, spray drying, 190 DEG C of inlet air temperature, 95 DEG C of leaving air temp, feed rate are controlled
20ml/min obtains powdered compound lactalbumin peptide product.Through detecting, lactalbumin peptide content prepared by the present embodiment (with
Butt meter) up to 96.1%；Peptide molecular weight distribution are as follows: account for 98% less than 1000 dalton.
Embodiment 3
50g lactalbumin is weighed, aquation is configured to 20.0wt% lactalbumin suspension, is added into lactalbumin suspension
Quality is 5/100000ths folic acid and millesimal niacin of lactalbumin amount, and whey egg is added into lactalbumin suspension
The Bioprase SP-20 and papain (being formed according to the weight ratio of 1:1) of white amount 0.5%, 50 DEG C of constant temperatures
Under, fully transparent solution is obtained after enzyme hydrolysis 8h in constant temperature enzymatic vessel.Through detecting, the degree of hydrolysis of lactalbumin is 47.3%, so
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C afterwards and keeps 20min, inactivates enzyme, controls degree of hydrolysis, so
Afterwards by the concentration of resulting lactalbumin peptide solution, spray drying, 190 DEG C of inlet air temperature, 95 DEG C of leaving air temp, feed rate are controlled
10ml/min obtains powdered compound lactalbumin peptide product.Through detecting, lactalbumin peptide content prepared by the present embodiment (with
Butt meter) up to 99.0%；Peptide molecular weight distribution are as follows: account for 99% less than 1000 dalton.
Embodiment 4
50g lactalbumin is weighed, aquation is configured to 25.0wt% lactalbumin suspension, is added into lactalbumin suspension
Quality be lactalbumin amount a ten thousandth folic acid and 2/1000ths niacin, lactalbumin is added into lactalbumin suspension
Bioprase SP-20 and the Denazyme AP (being formed according to the weight ratio of 5:1) of amount 1%, under 55 DEG C of constant temperatures,
Fully transparent solution is obtained in constant temperature enzymatic vessel after enzyme hydrolysis 10h.Through detecting, the degree of hydrolysis of lactalbumin is 52.4%, then will
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C and keeps 20min, inactivates enzyme, controls degree of hydrolysis, then dense
Contracting, spray drying, 190 DEG C of inlet air temperature of control, 95 DEG C of leaving air temp, feed rate 10ml/min obtain powdered compound whey
Albumen peptide product.Through detecting, lactalbumin peptide content (in terms of butt) prepared by the present embodiment is up to 96.5%；Peptide molecular weight point
Cloth range are as follows: account for 99% less than 1000 dalton.
Embodiment 5
50g lactalbumin is weighed, aquation is configured to 15.0wt% lactalbumin suspension, is added into lactalbumin suspension
Quality be lactalbumin amount 6/100000ths folic acid and 5/1000ths niacin, into lactalbumin suspension be added whey egg
The Bioprase SP-20 and papain (being formed according to the weight ratio of 3:2) of white amount 2%, under 60 DEG C of constant temperatures,
Fully transparent solution is obtained after enzyme hydrolysis 7h in constant temperature enzymatic vessel.Through detecting, the degree of hydrolysis of lactalbumin is 59.1%, then will
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C and keeps 10min, inactivates enzyme, controls degree of hydrolysis, then will
Resulting lactalbumin peptide solution concentration, spray drying control 190 DEG C of inlet air temperature, 95 DEG C of leaving air temp, feed rate
40ml/min obtains powdered compound lactalbumin peptide product.Through detecting, lactalbumin peptide content prepared by the present embodiment (with
Butt meter) up to 98.5%；Peptide molecular weight distribution are as follows: account for 99% less than 1000 dalton.
Embodiment 6
50g lactalbumin is weighed, aquation is configured to 10.0wt% lactalbumin suspension, is added into lactalbumin suspension
Quality be lactalbumin amount 2/100000ths folic acid and 5/1000ths niacin, into lactalbumin suspension be added whey egg
The Bioprase SP-20 and papain (being formed according to the weight ratio of 1:2) of white amount 0.4%, 65 DEG C of constant temperatures
Under, fully transparent solution is obtained after enzyme hydrolysis 9h in constant temperature enzymatic vessel.Through detecting, the degree of hydrolysis of lactalbumin is 49.6%, so
Reaction system lactalbumin enzyme hydrolyzate is brought rapidly up to 100 DEG C afterwards and keeps 20min, inactivates enzyme, controls degree of hydrolysis, so
It is concentrated, is spray-dried afterwards, 190 DEG C of inlet air temperature of control, 95 DEG C of leaving air temp, feed rate 20ml/min obtain powdered compound
Lactalbumin peptide product.Through detecting, lactalbumin peptide content (in terms of butt) prepared by the present embodiment is up to 99.5%；Peptide molecule
Measure distribution are as follows: account for 99% less than 1000 dalton.
Embodiment 7
The present embodiment is by carrying out elevated plus-maze model (Elevated Plus Maze, abbreviation EPM) examination to animal
It tests, adjustment effect of the research present invention to psychiatric system.Elevated plus-maze possesses most in small rodent animal anxiety test
It is widely applied, which can reduce animal innately to height and vacant lot aversion for detecting after taking anxiolytic
The case where.Rodent (such as rat, mouse) has exploratory behavior, is put into meeting initiative exploring open arms after Elevated plus-maze,
But fears and uphang open environment in open arms.Anxiolytic drugs can increase open arms inquiry activity, cause anxiety agent then opposite.
Elevated plus-maze has a pair of of open arms and a pair of of closure arm.Test mice is divided into 6 groups, it is every group 10 small
Mouse takes the lactalbumin peptide product of lactalbumin, diazepam (DZP), embodiment 1-6 to every group of test mice respectively, takes
Dosage see the table below 1.Will test mice adapt to a period of time after be immediately placed at the central platform of EPM, make its head face wherein 1
A open arms image the following data in record 5min using tracking and calculate the average value of every group of test data: 1. entering and open
It puts arm number (open arm entry, OE): entering the number of any open arms, entered in arm with four claws of rat
Subject to, one claw in midway exits completely from the arm then enters activity completion for this time；2. entering open arms time (open
Arm time, OT): into the time of open arms, unit is remembered with the second；3. enter closure arm number (close arm entry,
CE): entering the number of any closure arm, four claws of rat of being subject to enter in arm；4. entering the closure arm time
(close arm entry, CT): into the time of closure arm, unit is remembered with the second.By 1. -4. calculate separately out, test result is shown in
The following table 1:
1. entering the total degree (OE+CE) of open arms and closure arm: indicating the motion activity of rat；
2. entering open arms number ratio (OE%): i.e. open arms enter number/(OE+CE) × 100%；
3. open arms residence time ratio (OT%), i.e. open arms residence time/(OT+CT) × 100%.
OE% and OT% represents angst resistance effect index, and the bigger expression antianxiety relaxation effect of value is more obvious.
Table 1: result of the compound lactalbumin peptide product in mouse EPM test
Data are expressed as mean+SD (n=10) (*: indicating the p < 0.05 compared with negative control group)
Test result shows: when taking compound lactalbumin peptide product and diazepam (DZP) to test mice, always entering arm
Increase when number OE+CE, OT% and OE% value ratio take lactalbumin, and the dosage for taking compound whey protein peptide is bigger, it is right
The value answered is higher.Experiments have shown that: compound lactalbumin peptide product has significant angst resistance effect (P < on this Anxiety Model
0.05).Compound lactalbumin peptide product has certain relaxation effect to animal anxiety caused by irritability model, can significantly reduce
Level of serum cortisol (the important biochemical indicator that level of serum cortisol is pressure state) under emergency rating, the present invention is to strange
Central nervous system over-activity has certain inhibiting effect when mouse autonomic activities under environment.
Claims (10)
1. a kind of method for the dietetic food for preparing special medicine purposes, it is characterised in that the following steps are included:
(1) the lactalbumin suspension that preparation mass percent is 1%-25%；
(2) folic acid and quality of hundred a ten thousandths to a ten thousandth that quality is lactalbumin is added into lactalbumin suspension is
The niacin of lactalbumin one thousandth to 5/1000ths；
(3) compound protease is added into lactalbumin suspension to be digested；
(4) it will be concentrated after compound protein enzyme-deactivating；
(5) product after concentration is spray-dried to get compound lactalbumin peptide product；
The dietetic food of special medicine purposes obtained include quality be lactalbumin hundred a ten thousandths to a ten thousandth leaf
Acid and quality are the niacin of the one thousandth to 5/1000ths of lactalbumin, whey egg of the middle-molecular-weihydroxyethyl less than 1000 dalton
White peptide content is up to 98% or more.
2. according to the method for claim 1, it is characterised in that the preferred matter of concentration of lactalbumin suspension described in step (1)
Amount percentage is 5%-20%.
3. according to the method for claim 1, it is characterised in that the concentration preferably 100,000/zero point of step (2) described folic acid
5/five to 100,000.
4. according to the method for claim 1, it is characterised in that the content of compound protease described in step (3) is whey egg
0.1% one the 1% of white amount.
5. according to the method for claim 1, it is characterised in that compound protease described in step (3) is by bacillus subtilis protein
Enzyme, endotrypsin Denazyme AP, papain, flavor protease, bromelain, trypsase, neutral protein
Two or more any composition in enzyme, animal proteolytic enzyme, acid protease and pepsin.
6. according to the method for claim 5, it is characterised in that the composition of two kinds of compound proteases is according to (1-5):
The weight ratio of (5-1) forms.
7. according to the method for claim 1, it is characterised in that the time of the enzymatic hydrolysis of step (3) is 1-10 hours.
8. the dietetic food of special medicine purposes made from method according to claim 1-7.
9. the use that the dietetic food of special medicine purposes according to claim 8 is used to prepare the drug for the treatment of phrenoblabia
On the way.
10. the use that the dietetic food of special medicine purposes according to claim 8 is used to prepare the drug of antianxiety purposes
On the way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510998050.8A CN105476012B (en) | 2015-12-24 | 2015-12-24 | A kind of special medicine purposes formula food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510998050.8A CN105476012B (en) | 2015-12-24 | 2015-12-24 | A kind of special medicine purposes formula food and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105476012A CN105476012A (en) | 2016-04-13 |
| CN105476012B true CN105476012B (en) | 2019-04-05 |
Family
ID=55663585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510998050.8A Active CN105476012B (en) | 2015-12-24 | 2015-12-24 | A kind of special medicine purposes formula food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105476012B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110387396A (en) * | 2019-08-28 | 2019-10-29 | 苏州恒瑞健康科技有限公司 | A kind of method for hydrolysis and PURE WHEY of lactoalbumin soln |
| CN112690459B (en) * | 2020-12-23 | 2023-03-31 | 内蒙古蒙牛乳业（集团）股份有限公司 | Hydrolyzed whey protein, composition and clinical application thereof |
| CN112913962A (en) * | 2021-01-27 | 2021-06-08 | 江西恒顶食品有限公司 | Preparation method of protein powder |
| CN115137063A (en) * | 2022-07-14 | 2022-10-04 | 浙江益元素营养科技有限公司 | Special medical-use total-nutrient formula food for predigested protein and preparation method |
| CN115137064A (en) * | 2022-07-14 | 2022-10-04 | 浙江益元素营养科技有限公司 | Total nutrient formula food for predigestion special medical application and preparation method |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2985156B2 (en) * | 1991-04-18 | 1999-11-29 | 雪印乳業株式会社 | Milk-hydrolyzing peptide with high emulsifying properties and low allergenicity |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| CN1557196A (en) * | 2004-02-04 | 2004-12-29 | 高春平 | Pressure regulating, sleep improving natural nutrients |
| CN101496579B (en) * | 2008-01-28 | 2010-10-13 | 中国食品发酵工业研究院 | Special diet and foodstuffs formula containing small peptide for tumor patient |
| CN101518295B (en) * | 2008-02-25 | 2013-03-06 | 浙江科技学院 | Method for preparing powder rich in whey small peptides with molecular weight of 1000 daltons |
| CN101260421A (en) * | 2008-04-28 | 2008-09-10 | 浙江省农业科学院 | Method for preparing whey protein peptide by composite protease hydrolysis |
| CN104054828B (en) * | 2014-06-23 | 2016-05-25 | 中恩（天津）营养科技有限公司 | Infant formula of a kind of anti-albumen allergy and preparation method thereof |
-
2015
- 2015-12-24 CN CN201510998050.8A patent/CN105476012B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105476012A (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105476012B (en) | A kind of special medicine purposes formula food and preparation method thereof | |
| CN107141336A (en) | Yak Bone Protein peptide and preparation method with DPP IV inhibitory activity | |
| CN100999752B (en) | Antioxydizing peptide mixture from collagen and its preparation process and use | |
| CN104498570B (en) | Ocean fish protein peptide and preparation method thereof | |
| AU666531B2 (en) | Processes for the preparation of amylase inhibitor | |
| CN108715600B (en) | Oligopeptide for promoting proliferation and migration of intestinal mucosa epithelial cells and preparation method and application thereof | |
| Jan et al. | Effect of boiling on the antidiabetic property of enzyme treated sheep milk casein | |
| CN105949290A (en) | Chickpea protein powder and oligo-peptide powder and preparation methods and uses thereof | |
| CN109439717A (en) | A kind of extracting method of small molecule rhizoma polygonati polypeptide | |
| CN105400761B (en) | A kind of low molecular weight fibrinolysin and its preparation method and application | |
| CN112075529A (en) | Method for preparing antioxidant peptide powder by enzymolysis of whey protein powder and application of antioxidant peptide powder in milk tea powder | |
| CN109680027A (en) | A kind of grifola frondosus small peptide iron chelate and its preparation method and application | |
| CN110144374A (en) | A kind of egg white peptide and preparation method thereof that can promote union of wounded skin | |
| CN103330048A (en) | Preparation methods of sheep placenta polypeptide powder and soluble granules | |
| CN115536731A (en) | Preparation method of high-activity mung bean albumin glycopeptide-lowering | |
| CN103145800B (en) | Centipede zymolyte anti-thrombus polypeptide | |
| Zhou et al. | Peptidomic analysis reveals multiple protection of human breast milk on infants during different stages | |
| CN101829316A (en) | Lactalbumin hydrolysate and application thereof in preparing glucose-lowering medicament | |
| CN113789319A (en) | Method for separating maggot kinase from fly maggots and application thereof | |
| CN110452947A (en) | A kind of enzymatic hydrolysis process of egg albumen powder | |
| Nevinsky et al. | Six catalytic activities and cytotoxicity of immunoglobulin G and secretory immunoglobulin A from human milk | |
| CN102028932A (en) | Application of whey protein peptide in preparation of drugs and health food for enhancing immunity | |
| CN106107423B (en) | A kind of method of phenylalanine in removing rice protein | |
| CN101487003A (en) | Acid protease | |
| KR19990058644A (en) | Sericin Peptide Material with Alcohol Degradation Enhancement Effect and Cholesterol Inhibitory Effect and Mixed Drink and Health Food Using the Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200108 Address after: 236600 Building 5, harmony Road, Taihe Economic Development Zone, Fuyang, Anhui Patentee after: CHINJANE MEDICAL FOOD CO., LTD. Address before: 236600 Building 5, harmony Road, Taihe Economic Development Zone, Fuyang, Anhui Co-patentee before: Guangzhou Health Medicine Development Co., Ltd. Patentee before: CHINJANE MEDICAL FOOD CO., LTD. |